the Company’s intention is to permanently reinvest such foreign earnings. A determination of the amount of the unrecognized deferred tax liability related to undistributed earnings is not practicable.
In addition, the Company has not recognized a deferred tax liability for the difference between the financial statement and the tax basis of its investment in the common stock of its subsidiaries. Such difference relates primarily to $247 million of unremitted earnings earned by Witco’s foreign subsidiaries prior to the Merger on September 1, 1999. The Company does not expect this difference in basis to become subject to tax at the parent level, as it is the Company’s intention to permanently reinvest such foreign earnings.
The computation of basic earnings (loss) per common share is based on the weighted average number of common shares outstanding. Diluted earnings (loss) per share is based on the weighted average number of common and common share equivalents outstanding. The computation of diluted loss per share for fiscal year 2001 equals the basic calculation since common stock equivalents of 2,443 were antidilutive.
The Company is authorized to issue 500 million shares of $.01 par value common stock. There were 119,152,254 and 119,187,077 shares issued at year-end 2002 and 2001, respectively, of which 5,297,885 and 6,129,834 shares were held as treasury stock in 2002 and 2001, respectively.
The Company is authorized to issue 250,000 shares of preferred stock without par value, none of which are outstanding. On September 3, 1999, the Company declared a dividend distribution of one Preferred Share Purchase Right (Rights) on each outstanding share of common stock. These Rights entitle stockholders to purchase one one-hundredth of a share of a new series of junior participating preferred stock at an exercise price of $100. The Rights are only exercisable if a person or group acquires 15% or more of the Company’s common stock or announces a tender offer, which if successful, would result in ownership of 15% or more of the Company’s common stock.
The 1988 Long-Term Incentive Plan (1988 Plan), as amended, authorized the Board of Directors to grant stock options, stock appreciation rights, restricted stock and long-term performance awards covering up to 10 million shares to the officers and other key employees of C&K over a period of ten years through October 1998. Non-qualified and incentive stock options were granted under the 1988 plan at prices not less than 100% of the fair market value of the underlying common shares on the date of the grant. All outstanding options will expire not more than ten years and one month from the date of grant.
notes to consolidated financial statements continued
The 1993 Stock Option Plan for Non-Employee Directors, as amended in 1996, authorized 200,000 options to be granted to non-employee directors. The options vest over a two-year period and are exercisable over a ten year period from the date of grant, at a price equal to the fair market value of the underlying common shares on the date of grant.
The 1998 Long-Term Incentive Plan (1998 Plan) was approved by the shareholders of C&K in 1999. This plan authorizes the Board to grant stock options, stock appreciation rights, restricted stock and long-term performance awards to eligible employees and non-qualified stock options to non-employee directors over a ten-year period. During 2002, 2001 and 2000, non-qualified and incentive stock options were granted under the 1998 Plan at prices not less than 100% of the fair market value of the underlying common shares on the date of grant. All outstanding options will expire not more than ten years and one month from the date of grant. The 1998 Plan authorizes the Company to grant shares and options for shares of common stock equal to the sum of (i) the shares available for award under the 1988 Plan and the 1993 Stock Option Plan For Non-Employee Directors as of October 18, 1998 and (ii) the shares awarded under prior plans of C&K which were forfeited, expired, lapsed, not earned or tendered to pay the exercise price of options or withholding taxes. In 1999, the number of common shares reserved for issuance under the 1998 plan was increased by 2.8 million shares and, pursuant to the Merger, increased by an additional 5 million shares. Under the terms of the Merger, the shareholders also approved the conversion of all outstanding Witco options into options to purchase the Company’s common stock. These 4.7 million converted options expired 30 days after the Merger, and became available for grant under the 1998 Plan.
In October 2001, the Board of Directors approved the 2001 Employee Stock Option Plan (2001 Plan). The 2001 Plan authorizes the Board to grant up to 1 million non-qualified stock options to key non-officer employees. Options under the 2001 plan will be granted at prices not less than 100% of the fair market value of the underlying common shares on the date of grant and will expire not more than ten years and one month from the date of grant.
Under the 1988 Plan, 1,261,000 common shares have been transferred to an independent trustee to administer restricted stock awards for C&K’s long-term incentive program. At December 31, 2002, deferred compensation relating to such shares is $0.3 million and will be fully amortized by the end of 2004.
In 1996, Company granted long-term incentive awards from the 1988 Plan in the amount of 824,250 shares, which were earned at the end of 1998 based upon the achievement of certain financial criteria. The shares earned in 1998 vest ratably at 25% per year with the final installment payable at retirement. Compensation expense related to such shares was accrued over a six-year period.
In October 1999, the Company granted long-term incentive awards in the amount of 2,175,000 shares of restricted stock from the 1998 Plan. In connection with the Merger, vesting requirements relating to 300,000 shares of restricted stock were waived. The remaining 1,875,000 shares were earned as of December 31, 2000 based upon the achievement of certain financial criteria and will vest over a three-year period ending on January 1, 2003. Compensation expense relating to these shares is being accrued over a three-year period.
In January 2000, the Company granted long-term incentive awards under the 1998 Plan for a maximum of 2,707,250 shares to be earned at the end of 2002 if certain financial criteria were met. In January 2001, the January 2000 awards were cancelled and awards were granted for a maximum of 2,343,367 shares to be earned if certain vesting and financial criteria were met at the end of 2002. In January 2002, the Company granted long-term incentive awards under the 1998 Plan for a maximum of 1,052,000 shares to be earned at the end of 2004 if certain financial criteria are met for 2002 through 2004. In conjunction with this award, the remaining outstanding performance-based portion of the awards (1,655,000 shares) granted in January 2001 were cancelled.
In January 2003, the Board of Directors approved the grant of options covering 1,254,000 shares at the fair market value at the date of grant. These options will become exercisable in one-third increments over a three-year period.
As permitted under FASB Statement No. 123, "Accounting for Stock-Based Compensation” and FASB Statement No. 148, “Accounting for Stock-Based Compensation – Transitions and Disclosure,” the Company elected to continue its historical method of accounting for stock-based compensation in accordance with Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees." Accordingly, compensation expense has not been recognized for stock-based compensation plans other than restricted stock awards under the Company’s long-term incentive programs.
The following table summarizes the effect on net earnings (loss) and earnings (loss) per share if the Company had applied the fair value recognition provisions of Statement No. 123 to all stock-based employee compensation awards, the estimated fair value of options granted using the Black-Scholes model and the assumptions utilized in the model.
(In thousands, except per share data) | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
Net earnings (loss), as reported | | $ | (283,507 | ) | $ | (123,944 | ) | $ | 89,273 | |
Pro forma net earnings (loss) | | $ | (289,426 | ) | $ | (133,171 | ) | $ | 81,849 | |
Earnings (loss) per share: | | | | | | | | | | |
Basic – as reported | | $ | (2.50 | ) | $ | (1.10 | ) | $ | 0.78 | |
Basic – pro forma | | $ | (2.55 | ) | $ | (1.18 | ) | $ | 0.72 | |
Diluted – as reported | | $ | (2.45 | ) | $ | (1.10 | ) | $ | 0.78 | |
Diluted – pro forma | | $ | (2.50 | ) | $ | (1.18 | ) | $ | 0.71 | |
Average fair value of options granted | | $ | 3.08 | | $ | 3.97 | | $ | 4.35 | |
Assumptions: | | | | | | | | | | |
Dividend yield | | | 2.5 | % | | 2.0 | % | | 1.9 | % |
Expected volatility | | | 48 | % | | 52 | % | | 54 | % |
Risk-free interest rate | | | 3.5 | % | | 5.0 | % | | 5.8 | % |
Expected life (in years) | | | 8 | | | 8 | | | 8 | |
Changes during 2002, 2001 and 2000 in shares under option are summarized as follows:
| | Price Per Share | | | |
| |
| | | |
| | Range | | Average | | Shares | |
| |
| |
| |
| |
Outstanding at 12/31/99 | | $ | 3.13-26.41 | | $ | 12.81 | | 10,233,246 | |
Granted | | | 8.16-8.34 | | | 8.16 | | 2,168,500 | |
Exercised | | | 5.22-13.00 | | | 8.10 | | (45,357 | ) |
Lapsed | | | 8.16-26.41 | | | 12.61 | | (585,067 | ) |
| |
|
| |
|
| |
| |
Outstanding at 12/31/00 | | | 3.13-26.41 | | | 11.98 | | 11,771,322 | |
Granted | | | 7.92-10.81 | | | 7.93 | | 1,760,866 | |
Exercised | | | 3.13-8.34 | | | 5.20 | | (111,759 | ) |
Lapsed | | | 8.16-26.41 | | | 15.75 | | (346,142 | ) |
| |
|
| |
|
| |
| |
Outstanding at 12/31/01 | | | 5.22-26.41 | | | 11.39 | | 13,074,287 | |
Granted | | | 7.25 | | | 7.25 | | 1,272,430 | |
Exercised | | | 5.22-8.34 | | | 7.59 | | (436,149 | ) |
Lapsed | | | 7.92-26.41 | | | 16.95 | | (771,165 | ) |
| |
|
| |
|
| |
| |
Outstanding at 12/31/02 | | $ | 5.22-26.41 | | $ | 10.79 | | 13,139,403 | |
| |
|
| |
|
| |
| |
Exercisable at 12/31/00 | | $ | 3.13-26.41 | | $ | 14.15 | | 6,718,519 | |
| |
|
| |
|
| |
| |
Exercisable at 12/31/01 | | $ | 5.22-26.41 | | $ | 12.78 | | 9,073,974 | |
| |
|
| |
|
| |
| |
Exercisable at 12/31/02 | | $ | 5.22-26.41 | | $ | 11.52 | | 10,699,627 | |
| |
|
| |
|
| |
| |
Shares available for grant at year-end 2002 and 2001 were 6,148,135 and 5,102,946, respectively.
The following table summarizes information concerning currently outstanding and exercisable options:
Range of Exercise Prices | | Number Outstanding at End of 2002 | | Weighted Average Remaining Contractual Life | | Weighted Average Exercise Price | | Number Exercisable at end of 2002 | | Weighted Average Exercise Price | |
| |
| |
| |
| |
| |
| |
$ | 5.22-7.92 | | 3,028,357 | | 9.2 | | $ | 7.61 | | 806,929 | | $ | 7.83 | |
$ | 8.16-8.35 | | 5,396,985 | | 7.0 | | $ | 8.27 | | 5,181,970 | | $ | 8.28 | |
$ | 10.81-14.35 | | 1,980,508 | | 3.6 | | $ | 13.30 | | 1,977,175 | | $ | 13.30 | |
$ | 14.50-26.41 | | 2,733,553 | | 3.6 | | $ | 17.47 | | 2,733,553 | | $ | 17.47 | |
| | |
| |
| |
|
| |
| |
|
| |
| | | 13,139,403 | | 6.3 | | $ | 10.79 | | 10,699,627 | | $ | 11.52 | |
| | |
| |
| |
|
| |
| |
|
| |
The Company has an Employee Stock Ownership Plan that is offered to eligible employees of the Company and certain of its subsidiaries. The Company makes contributions equivalent to a stated percentage of employee contributions. The Company’s contributions were $2.8 million in 2002, $3.6 million in 2001 and $3.3 million in 2000.
Effective June 1, 2001, the Company established an Employee Stock Purchase Plan. This plan permits eligible employees to annually elect to have up to 10% of their compensation withheld for the purchase of shares of the Company’s common stock at 85% of the average of the high and low sale prices on the date of purchase. As of December 31, 2002, 232,512 shares were purchased under this plan.
PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS
The Company has several defined benefit and defined contribution pension plans covering substantially all of its domestic employees and certain international employees. Benefits under the defined benefit plans are primarily based on the employees’ years of service and compensation during employment. The Company’s funding policy for the defined benefit plans is based on contributions at the minimal annual amounts required by law plus such amounts as the Company may deem appropriate. Contributions for the defined contribution plans are determined as a percentage of the covered employees’ salary. Plan assets consist of publicly traded securities and investments in commingled funds administered by independent investment advisors.
Employees of international locations are covered by various pension benefit arrangements, some of which are considered to be defined benefit plans for financial reporting purposes. Assets of these plans are comprised primarily of insurance contracts and financial
notes to consolidated financial statements continued
securities. Benefits under these plans are primarily based upon levels of compensation. Funding policies are based on legal requirements, tax considerations and local practices.
The Company also provides health and life insurance benefits for certain retired and active employees and their beneficiaries and covered dependents for substantially all of its domestic employees and certain international employees. These plans are generally not pre-funded and are paid by the Company as incurred, except for certain inactive government related plans.
| | Defined Benefit Plans | | | | | |
| |
| | | | | |
| | Qualified Domestic Plans | | International and Non-Qualified Plans | | Post-Retirement Health Care Plans | |
| |
| |
| |
| |
(In thousands) | | 2002 | | 2001 | | 2002 | | 2001 | | 2002 | | 2001 | |
| |
| |
| |
| |
| |
| |
| |
Change in projected benefit obligation: | | | | | | | | | | | | | | | | | | | |
Benefit obligation at beginning of year | | $ | 619,981 | | $ | 601,533 | | $ | 184,773 | | $ | 203,241 | | $ | 216,511 | | $ | 212,411 | |
Service cost | | | 6,705 | | | 6,819 | | | 6,537 | | | 5,936 | | | 1,604 | | | 1,539 | |
Interest cost | | | 42,245 | | | 43,185 | | | 11,796 | | | 11,021 | | | 14,497 | | | 15,148 | |
Plan participants’ contributions | | | — | | | — | | | 938 | | | 806 | | | 734 | | | 741 | |
Plan amendments | | | 98 | | | 699 | | | (83 | ) | | 396 | | | — | | | 2,353 | |
Actuarial losses | | | 27,300 | | | 12,954 | | | 16,639 | | | 5,410 | | | 8,510 | | | 450 | |
Foreign currency exchange rate changes | | | — | | | — | | | 20,310 | | | (8,920 | ) | | 61 | | | (292 | ) |
Divestitures | | | — | | | — | | | — | | | (708 | ) | | — | | | — | |
Benefits paid | | | (46,788 | ) | | (45,553 | ) | | (13,564 | ) | | (8,259 | ) | | (17,839 | ) | | (16,411 | ) |
Curtailments | | | (1,420 | ) | | 2,200 | | | — | | | (13,150 | ) | | — | | | 572 | |
Settlements | | | — | | | (3,886 | ) | | (793 | ) | | (11,000 | ) | | — | | | — | |
Special termination benefits | | | — | | | 2,030 | | | — | | | — | | | — | | | — | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Projected benefit obligation at end of year | | $ | 648,121 | | $ | 619,981 | | $ | 226,553 | | $ | 184,773 | | $ | 224,078 | | $ | 216,511 | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Change in plan assets: | | | | | | | | | | | | | | | | | | | |
Fair value of plan assets at beginning of year | | $ | 539,294 | | $ | 603,581 | | $ | 80,725 | | $ | 114,092 | | $ | 34,580 | | $ | 39,776 | |
Actual return on plan assets | | | (41,058 | ) | | (29,188 | ) | | (4,425 | ) | | (2,065 | ) | | (1,832 | ) | | (2,401 | ) |
Foreign currency exchange rate changes | | | — | | | — | | | 8,834 | | | (5,714 | ) | | — | | | — | |
Employer contributions | | | 6,880 | | | 13,423 | | | 10,716 | | | 6,280 | | | 14,780 | | | 12,875 | |
Plan participants’ contributions | | | — | | | — | | | 938 | | | 806 | | | 734 | | | 741 | |
Divestitures | | | — | | | — | | | — | | | (708 | ) | | — | | | — | |
Benefits paid | | | (46,788 | ) | | (45,553 | ) | | (13,564 | ) | | (8,259 | ) | | (17,839 | ) | | (16,411 | ) |
Settlements | | | — | | | (2,969 | ) | | (793 | ) | | (23,707 | ) | | — | | | — | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Fair value of plan assets at end of year | | $ | 458,328 | | $ | 539,294 | | $ | 82,431 | | $ | 80,725 | | $ | 30,423 | | $ | 34,580 | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Funded status: | | | | | | | | | | | | | | | | | | | |
Funded status | | $ | (189,793 | ) | $ | (80,687 | ) | $ | (144,122 | ) | $ | (104,048 | ) | $ | (193,655 | ) | $ | (181,931 | ) |
Unrecognized transition asset | | | (47 | ) | | (54 | ) | | 1,759 | | | 2,015 | | | — | | | — | |
Unrecognized actuarial (gain) loss | | | 206,464 | | | 84,598 | | | 32,145 | | | 5,557 | | | 4,276 | | | (10,197 | ) |
Unrecognized prior service cost | | | 348 | | | 313 | | | 2,479 | | | 3,444 | | | (4,617 | ) | | (7,455 | ) |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Net amount recognized | | $ | 16,972 | | $ | 4,170 | | $ | (107,739 | ) | $ | (93,032 | ) | $ | (193,996 | ) | $ | (199,583 | ) |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Amounts recognized in the consolidated balance sheet consist of: | | | | | | | | | | | | | | | | | | | |
Prepaid benefit costs | | $ | 24,271 | | $ | 17,223 | | $ | 4,971 | | $ | 4,003 | | $ | — | | $ | — | |
Accrued benefit liabilities | | | (183,315 | ) | | (75,937 | ) | | (132,924 | ) | | (103,647 | ) | | (193,996 | ) | | (199,583 | ) |
Intangible asset | | | 258 | | | 313 | | | 3,340 | | | 4,384 | | | — | | | — | |
Accumulated other comprehensive loss | | | 175,758 | | | 62,571 | | | 16,874 | | | 2,228 | | | — | | | — | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Net amount recognized | | $ | 16,972 | | $ | 4,170 | | $ | (107,739 | ) | $ | (93,032 | ) | $ | (193,996 | ) | $ | (199,583 | ) |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
| | Defined Benefit Plans | | | | | | | |
| |
| | | | | | | |
| | Qualified Domestic Plans | | International and Non-Qualified Plans | | Post-Retirement Health Care Plans | |
| |
| |
| |
| |
(In thousands) | | 2002 | | 2001 | | 2000 | | 2002 | | 2001 | | 2000 | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
Components of net periodic benefit cost (credit): | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Service cost | | $ | 6,705 | | $ | 6,819 | | $ | 7,959 | | $ | 6,537 | | $ | 5,936 | | $ | 6,991 | | $ | 1,604 | | $ | 1,539 | | $ | 1,864 | |
Interest cost | | | 42,245 | | | 43,185 | | | 43,463 | | | 11,796 | | | 11,021 | | | 11,416 | | | 14,497 | | | 15,148 | | | 15,567 | |
Expected return on plan assets | | | (56,244 | ) | | (56,141 | ) | | (52,468 | ) | | (6,228 | ) | | (6,094 | ) | | (7,473 | ) | | (3,179 | ) | | (3,668 | ) | | (3,795 | ) |
Amortization of prior service cost | | | 63 | | | 414 | | | 487 | | | 955 | | | 978 | | | 1,004 | | | (2,838 | ) | | (4,176 | ) | | (4,877 | ) |
Amortization of unrecognized transition obligation | | | (6 | ) | | (3 | ) | | 3 | | | 189 | | | 190 | | | 56 | | | — | | | — | | | — | |
Recognized actuarial (gains) losses | | | 164 | | | (29 | ) | | (38 | ) | | 161 | | | (207 | ) | | (297 | ) | | (936 | ) | | (1,447 | ) | | (1,363 | ) |
Curtailment (gain) loss recognized | | | 1,154 | | | 7,045 | | | (200 | ) | | — | | | (13,101 | ) | | (136 | ) | | — | | | (1,055 | ) | | — | |
Settlement (gain) loss recognized | | | — | | | 873 | | | — | | | 330 | | | 7,095 | | | (61 | ) | | — | | | — | | | — | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Net periodic benefit cost (credit) | | $ | (5,919 | ) | $ | 2,163 | | $ | (794 | ) | $ | 13,740 | | $ | 5,818 | | $ | 11,500 | | $ | 9,148 | | $ | 6,341 | | $ | 7,396 | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Weighted average assumptions: | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Discount rate | | | 6.75 | % | | 7.00 | % | | 7.56 | % | | 5.96 | % | | 5.91 | % | | 6.52 | % | | 6.75 | % | | 7.00 | % | | 7.55 | % |
Expected return on plan assets | | | 9.50 | % | | 9.50 | % | | 9.50 | % | | 6.99 | % | | 7.22 | % | | 7.02 | % | | 9.50 | % | | 9.50 | % | | 9.50 | % |
Rate of compensation increase | | | 4.00 | % | | 4.00 | % | | 4.25 | % | | 3.25 | % | | 3.35 | % | | 3.45 | % | | — | | | — | | | — | |
The assumed health care cost trend rate ranged from 9% - 9.5% and is assumed to decrease gradually to 5% in 2011 and remain level thereafter.
Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plan. A one-percentage-point change in assumed health care cost trend rates would have the following effects:
(In thousands) | | One-Percentage Point Increase | | One-Percentage Point Decrease | |
| |
| |
| |
Effect on the aggregate of the service and interest cost components of net periodic post-retirement health care benefit cost for 2002 | | $ | 1,197 | | $ | (1,156 | ) |
Effect on accumulated post-retirement benefit obligation for health care benefits as of December 31, 2002 | | $ | 13,909 | | $ | (13,897 | ) |
For pension plans with accumulated benefit obligations in excess of plan assets, the aggregate accumulated benefit obligation was $814.1 million in 2002 and $696.5 million in 2001, and the aggregate fair value of plan assets was $529.7 million in 2002 and $547.6 million in 2001.
The Company’s net cost of pension plans, including defined contribution plans, was $23.6 million, $23.2 million, and $28.9 million in 2002, 2001 and 2000, respectively.
notes to consolidated financial statements continued
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
Effective January 1, 2001, the Company adopted FASB Statement No. 133, “Accounting for Derivative Instruments and Hedging Activities,” and Statement No. 138, “Accounting for Certain Derivative Instruments and Certain Hedging Activities” (the “Statements”).
The Company’s activities expose its earnings, cash flows and financial position to a variety of market risks, including the effects of changes in foreign currency exchange rates and interest rates. The Company maintains a foreign currency risk-management strategy that uses derivative instruments as needed to mitigate risk against foreign currency movements and to manage interest rate volatility. In accordance with the Statements, the Company recognizes in earnings changes in the fair value of all derivatives designated as fair value hedging instruments that are highly effective, and recognizes in accumulated other comprehensive loss (AOCL) changes in the fair value of all derivatives designated as cash flow hedging instruments that are highly effective. The Company does not enter into derivative instruments for trading or speculative purposes.
The Company uses interest rate swap contracts, which expire in 2003, as cash flow hedges to convert its $57.1 million Euro denominated variable rate debt to fixed rate debt. Each interest rate swap contract is designated with the principal balance and the term of the specific debt obligation. These contracts involve the exchange of interest payments over the life of the contract without an exchange of the notional amount upon which the payments are based. The differential to be paid or received as interest rates change is recognized as an adjustment to interest expense. In the event of early extinguishment of the designated debt obligations, any realized or unrealized gain or loss from the swap would be recognized in earnings coincident with any extinguishment gain or loss. In December 2002, the Company paid down $11.6 million of its Euro denominated variable rate debt and terminated the related portion of its interest rate swap contract, which resulted in a loss of $173,000 recorded to interest expense.
The Company also has equity option contracts that consist of sold put option contracts and purchased call option contracts at various strike prices. The Company entered into these contracts to hedge the expense variability associated with its obligations under its long-term incentive plans. The sold put option contracts and purchased call option contracts cover 3.2 million shares of common stock, with a weighted average strike price of $16.52 per share for the put contracts and $16.69 per share for the call contracts. These contracts have an expiration date of February 14, 2003 and require net cash settlement. As of December 31, 2002, a liability of $33.8 million has been included in accrued expenses to reflect the unrealized loss on these option contracts based on the year-end closing price of the Company’s common stock. In February 2003, the Company settled these equity option contracts for $35.1 million and entered into a new equity option contract that consists of a sold put option contract and a purchased call option contract, covering 3.2 million shares of common stock, with a strike price of $5.66 per share for the put contract and $5.75 per share for the call contract. The new contract has an expiration date of May 9, 2003 and requires net cash settlement.
The Company has designated a portion of the equity option contracts as cash flow hedges of the risk associated with the unvested, unpaid awards under its long-term incentive plans. Changes in market value related to the portion of the option contracts designated and effective as hedges have been recorded as a component of AOCL. The amount included in AOCL ($2 million at December 31, 2002) is subject to changes in the stock price and is being amortized ratably to selling, general and administrative expense (SG&A) over the remaining service periods of the hedged long-term incentive plans. Changes in market value related to the remaining portion of the option contracts are recognized in SG&A. Based on the December 31, 2002 closing price of the Company’s common stock, the anticipated amortization from AOCL to SG&A over the next 12 months will be approximately $1 million.
The Company used an interest rate swap contract as a fair value hedge to convert $300 million of its fixed rate 8.5% notes into variable rate debt. On March 24, 2001, the swap contract was terminated and the Company received cash proceeds of $21.9 million in settlement of the contract, which represented the market value of the contract on the date of termination. In accordance with the Statements, as they relate to fair value hedge accounting, the $21.9 million was recorded as an increase to long-term debt and is being amortized to interest expense over the life of the notes. The unamortized balance at December 31, 2002 and 2001 was $12.1 million and $17.5 million, respectively.
The Company also has exposure to changes in foreign currency exchange rates resulting from transactions entered into by the Company and its foreign subsidiaries in currencies other than their local currency (primarily trade payables and receivables). The Company is also exposed to currency risk on intercompany transactions (including intercompany loans). The Company manages these transactional currency risks on a consolidated basis, which allows it to net its trade payable and receivable exposure. The Company purchases foreign currency forward contracts, primarily denominated in Euros, Canadian dollars, Swiss francs and Singapore dollars, to hedge its transaction exposure. The aggregate notional amount of these contracts at December 31, 2002 is approximately $536 million. These contracts are generally settled on a monthly basis. Realized and unrealized gains and losses on foreign currency forward contracts are recognized in other expense, net, to offset the impact of valuing recorded foreign currency trade payables, receivables and intercompany transactions. The Company has not designated these derivatives as hedges, although it believes these instruments reduce the Company’s exposure to foreign currency risk. The net effect of the realized and unrealized gains and losses on these derivatives and the underlying transactions is not significant at December 31, 2002.
The following table summarizes the (gains)/losses resulting from changes in the market value of the Company’s fair value and cash flow hedging instruments and the amortization of (gains)/losses related to certain cash flow hedges for the years ended December 31, 2002 and 2001.
(In thousands) | | 2002 | | 2001 | |
| |
| |
| |
| | | | | | | |
Fair value hedges (in other expense, net) | | $ | (2 | ) | $ | (582 | )* |
| |
|
| |
|
| |
Cash flow hedges (in AOCL): | | | | | | | |
Balance at beginning of year | | $ | 2,546 | | $ | — | |
Interest rate swap contracts | | | (313 | ) | | 1,196 | * |
Equity option contracts–change in market value | | | 6,558 | | | 3,322 | |
Equity option contracts–amortization to selling, general and administrative | | | (5,953 | ) | | (1,972 | ) |
| |
|
| |
|
| |
Balance at end of year | | $ | 2,838 | | $ | 2,546 | |
| |
|
| |
|
| |
| * | Includes the Statements implementation impact gain of $567,000 ($346,000 after-tax) related to the fair value hedges and a loss of $234,000 related to the interest rate swap cash flow hedges. |
FINANCIAL INSTRUMENTS
As discussed in the Derivative Instruments and Hedging Activities note above, the Company enters into interest rate swap contracts to modify the interest characteristics of some of its outstanding debt and purchases foreign currency forward contracts to mitigate its exposure to changes in foreign currency exchange rates of recorded transactions (principally foreign currency trade receivables and payables and intercompany transactions).
At December 31, 2002 and 2001, the Company had outstanding interest rate swap contracts with an aggregate notional amount of $57.1 million and $58 million, respectively. These contracts are used to convert the Company’s variable rate Euro denominated debt to fixed rate debt.
At December 31, 2002, the Company had outstanding foreign currency forward contracts with an aggregate notional amount of approximately $536 million to hedge foreign currency risk on foreign currency accounts receivable and payable and intercompany loans. These forward contracts are generally outstanding for one month and are primarily denominated in Euros, Canadian dollars, Swiss francs and Singapore dollars. At December 31, 2001, the Company had outstanding foreign currency forward contracts with an aggregate notional amount of approximately $356 million.
All contracts have been entered into with major financial institutions. The risk associated with these transactions is the cost of replacing these agreements at current market rates, in the event of default by the counterparties. Management believes the risk of incurring such losses is remote.
The carrying amounts for cash, accounts receivable, other current assets, accounts payable and other current liabilities approximate their fair value because of the short-term maturities of these instruments. The fair value of long-term debt is based primarily on quoted market values. For long-term debt that has no quoted market value, the fair value is estimated by discounting projected future cash flows using the Company’s incremental borrowing rate. The fair value of interest rate swap and foreign currency forward contracts is the amount at which the contracts could be settled based on quotes provided by investment banking firms.
The following table presents the carrying amounts and estimated fair values of material financial instruments used by the Company
notes to consolidated financial statements continued
in the normal course of its business. The carrying amounts of the interest rate swap contracts and foreign currency forward contracts are included in either other assets or other liabilities.
| | 2002 | |
| |
| |
(In thousands) | | Carrying Amount | | Fair Value | |
| |
| |
| |
Long-term debt | | $ | (1,261,847 | ) | $ | (1,224,891 | ) |
Interest rate swap contracts | | $ | (884 | ) | $ | (884 | ) |
Foreign currency forward contracts | | $ | 38 | | $ | 38 | |
| | | | | | | |
| | 2001 | |
| |
| |
| | | Carrying Amount | | | Fair Value | |
| |
|
| |
|
| |
Long-term debt | | $ | (1,392,833 | ) | $ | (1,407,996 | ) |
Interest rate swap contracts | | $ | (1,197 | ) | $ | (1,197 | ) |
Foreign currency forward contracts | | $ | (111 | ) | $ | (63 | ) |
ANTITRUST INVESTIGATIONS AND RELATED MATTERS
Antitrust Investigations
The Company and certain of its subsidiaries, together with other domestic and foreign companies, are currently the subject of coordinated criminal investigations being conducted by the United States Department of Justice (the “DOJ”) and the Canadian Competition Bureau (the “CCB”) and a coordinated civil investigation being conducted by the European Commission (together with the DOJ and the CCB, the “Governmental Authorities”) with respect to possible antitrust violations relating to the sale and marketing of certain rubber processing chemicals, ethylene propylene diene monomer (“EPDM”) and heat stabilizers. The investigations concern possible anticompetitive practices, including price fixing and customer or market allocations, undertaken by the Company and such subsidiaries and certain of their officers and employees. According to reports in the press, The Japan Fair Trade Commission (the “JFTC”) is conducting an investigation regarding heat stabilizers, impact modifiers and processing aids for plastic. The Company has not been contacted by the JFTC. The Company is actively cooperating with the Governmental Authorities regarding such investigations. Since inception of the investigations, the Company has been conducting its own internal investigation with the assistance of special counsel. Neither the Company, any of its subsidiaries, nor any individual has, to date, been charged in connection with the investigations.
It is the Company’s understanding that the investigations by the Governmental Authorities are, as previously stated, focused on rubber processing chemicals, including accelerators, antioxidants and antiozonants (with 2002 sales of $206 million), EPDM (with 2002 sales of $135 million), and heat stabilizers, including tin-based stabilizers and precursors, mixed metal stabilizers and epoxidized soybean oil (“ESBO”) (with 2002 sales of approximately $220 million).
With respect to rubber chemicals, the Company has held preliminary discussions with the DOJ regarding a possible plea to violations of antitrust laws. At this time, the Company cannot predict the outcome of those discussions, including the timing or the terms of any agreement with the DOJ or the amount of any fines that may be imposed. Moreover, at this time, the Company cannot determine the extent to which criminal or civil fines or other sanctions might be imposed by the other Governmental Authorities. The Company has met and is continuing to meet with the Governmental Authorities in an attempt to resolve all matters relating to the investigations.
With respect to EPDM and heat stabilizers, the Company and its affiliates that are subject to the investigations have received from each of the Governmental Authorities verbal or written assurances of conditional amnesty from prosecution and fines. The European Commission’s grant of conditional amnesty with respect to heat stabilizers is presently limited to tin-based stabilizers and their precursors, but the Company expects to be granted conditional amnesty by the European Commission with respect to mixed metal stabilizers and ESBO in the near future. The assurances of conditional amnesty are conditioned upon several factors, including continued cooperation with the Governmental Authorities.
As previously stated, the Company is conducting a continuing internal investigation of the matters under investigation by the Governmental Authorities, including a review as to any improper or criminal conduct by current and former officers and employees of the Company and its affected subsidiaries. Further, the Company and its special counsel assisting in the investigation are reviewing all other areas of the Company’s business and products to determine compliance with applicable antitrust law and with the Company’s antitrust guidelines and policies. In connection with the investigations, a senior officer of the Company has been placed on paid administrative leave.
The resolution of any possible antitrust violations against the Company and certain of its subsidiaries and the resolution of any civil claims
now pending or hereafter asserted against them may have a material adverse effect on the Company’s financial condition, results of operations and prospects. No assurances can be given regarding the outcome or timing of these matters. Through December 31, 2002, the Company has incurred $6.3 million (pre-tax) of antitrust investigation costs, and expects to continue to incur substantial costs until all antitrust investigations are concluded.
The Company has named a compliance officer who will report to the Chief Executive Officer and the Chairman of the Audit Committee. The primary duties of the compliance officer will be to administer the Company’s compliance program in accordance with policies and procedures adopted by the Board of Directors of the Company.
State Class Actions
The Company and certain of its subsidiaries along with other companies, have been named as defendants in twenty putative indirect purchaser class action lawsuits filed during the period from October, 2002 through December, 2002 in state courts in seventeen states and in the District of Columbia. The putative class in each of the actions comprises all persons within each of the applicable states and the District of Columbia who purchased tires other than for resale that were manufactured using rubber processing chemicals sold by the defendants since 1994. The complaints principally allege that the defendants agreed to fix, raise, stabilize and maintain the price of rubber processing chemicals used as part of the tire manufacturing process in violation of state antitrust and consumer protection laws and that this illegal conspiracy caused injury to individuals who paid more to purchase tires as a result of such anticompetitive activities. The plaintiffs seek, among other things, treble damages of an unspecified amount, interest and attorneys’ fees and costs. The Company and its defendant subsidiaries have filed or intend to file motions to dismiss on substantive and personal jurisdictional grounds or answers with respect to each of these actions.
These actions are in early procedural stages of litigation and, accordingly, the Company cannot predict their outcome. The Company and its defendant subsidiaries believe that they have substantial defenses to these actions and intend to defend vigorously all such actions.
CONTINGENCIES AND ENVIRONMENTAL MATTERS
The Company is involved in claims, litigation, administrative proceedings and investigations of various types in various jurisdictions. A number of such matters involve, or may involve, claims for a material amount of damages and relate to or allege environmental liabilities, including clean-up costs associated with hazardous waste disposal sites, natural resource damages, property damage and personal injury. The Company and some of its subsidiaries have been identified by federal, state or local governmental agencies, and by other potentially responsible parties (each a "PRP") under the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, or comparable state statutes, as a PRP with respect to costs associated with waste disposal sites at various locations in the United States. In addition, the Company is involved with environmental remediation and compliance activities at some of its current and former sites in the United States and abroad.
Each quarter, the Company evaluates and reviews estimates for future remediation, and operating and maintenance costs directly related to remediation, to determine appropriate environmental reserve amounts. For each site, a determination is made of the specific measures that are believed to be required to remediate the site, the estimated total cost to carry out the remediation plan, the portion of the total remediation costs to be borne by the Company and the anticipated time frame over which payments toward the remediation plan will occur. The total amount accrued for such environmental liabilities at December 31, 2002 was $128.8 million. The Company estimates its potential environmental liability to range from $116 million to $142 million at December 31, 2002. It is possible that the Company's estimates for environmental remediation liabilities may change in the future should additional sites be identified, further remediation measures be required or undertaken, the interpretation of current laws and regulations be modified or additional environmental laws and regulations be enacted.
On May 21, 1997, the United States District Court, Eastern District of Arkansas (the “Court”), entered an order finding that Uniroyal Chemical Co./Cie (Uniroyal) (a wholly owned subsidiary of the Company) is jointly and severally liable to the United States and Hercules Incorporated (Hercules) and Uniroyal are liable to each other in contribution with respect to the remediation of the Vertac
notes to consolidated financial statements continued
Chemical Corporation site in Jacksonville, Arkansas. On October 23, 1998, the Court entered an order granting the United States' motion for summary judgment against Uniroyal and Hercules for removal and remediation costs of $102.9 million at the Vertac site. On February 3, 2000, after trial on the allocation of these costs, the Court entered an order finding Uniroyal liable to the United States for approximately $2.3 million and liable to Hercules in contribution for approximately $700,000. On April 10, 2001, the United States Court of Appeals for the Eighth Circuit (the “Appeals Court”) (i) reversed a decision in favor of the United States and against Hercules with regard to the issue of divisibility of harm and remanded the case back to the Court for a trial on the issue; (ii) affirmed the finding of arranger liability against Uniroyal; and (iii) set aside the findings of contribution between Hercules and Uniroyal by the Court pending a decision upon remand. The Appeals Court also deferred ruling on all constitutional issues raised by Hercules and Uniroyal pending subsequent findings by the Court. On June 6, 2001, the Appeals Court denied Uniroyal’s petition for rehearing by the full Appeals Court on the Appeals Court’s finding of arranger liability against Uniroyal and on December 10, 2001, Uniroyal’s Writ of Certiorari with the United States Supreme Court with regard to the issues of its arranger liability was denied. On December 12, 2001, the Court concluded hearings pursuant to the April 10, 2001 remand by the Appeals Court, and briefing on the issue of divisibility was completed in January 2003. A decision from the Court is expected during the second quarter of 2003.
The Company has standby letters of credit and guarantees with various financial institutions. At December 31, 2002, the Company had $57.4 million of outstanding letters of credit and guarantees primarily related to its environmental remediation liabilities, insurance obligations and a potential tax exposure. Only one of these outstanding standby letters of credit falls within the scope of FASB Interpretation No. 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.” This standby letter of credit, in the amount of $12.7 million, relates to a potential tax exposure, of which $10.2 million has been accrued at December 31, 2002.
The Company intends to assert all meritorious legal defenses and all other equitable factors which are available to it with respect to the above matters. The resolution of these matters could have a material adverse effect on its consolidated results of operations in any given year or other reporting period if a number of these matters are resolved unfavorably.
BUSINESS SEGMENT DATA
Pursuant to FASB Statement No. 131, "Disclosures about Segments of an Enterprise and Related Information," the Company has defined its reporting segments into two major business categories, "Polymer Products" and "Specialty Products." On April 12, 2002, the Company announced certain modifications within its financial reporting segments to reflect the current management and operating structure in its portfolio of businesses. First, petroleum additives was reclassified from the “Other” category to the Polymer Additives segment. This change reflects the similarity of product and product enhancing characteristics of these additives, as well as shared manufacturing processes and facilities. Second, industrial specialties (divested in June 2002) was reclassified from the Crop Protection segment to the “Other” category. Third, glycerine and fatty acids was reclassified from the “Other” category into plastic additives (included in the Polymer Additives segment). This change recognizes that glycerine and fatty acids are a byproduct of in-house production for use in the plastic additives business. Fourth, trilene (a minor product line with less than $4 million in annual sales) was reclassified from petroleum additives (included in the Polymer Additives segment) to EPDM (included in the Polymers segment). The former classification was predicated on the product’s use in lubricant applications, while the new designation is consistent with the chemistry of trilene, which is a liquid form of EPDM. After adjusting for these modifications, Polymer Products includes reporting segments of Polymer Additives (plastic additives, rubber additives, petroleum additives and urethane additives), Polymers (EPDM, urethane polymers and the nitrile rubber joint venture—sold December 2001) and Polymer Processing Equipment (specialty processing equipment and controls). Specialty Products includes reporting segments of OrganoSilicones (silanes and specialty silicones), Crop Protection (specialty actives and the Gustafson joint venture) and Other (refined products, industrial specialties—sold June 2002, and industrial colors—sold December 2001).
The accounting policies of the operating segments are the same as those described in the Accounting Policies footnote. The Company evaluates a segment's performance based on several factors, of which a primary financial measure is operating profit. In computing operating profit (loss) by segment, the following items have not been deducted: general corporate expenses, amortization of intangibles, facility closures, severance and related costs, antitrust investigation costs, impairment of long-lived assets, interest expense, other
expense, net, and income taxes. Corporate assets are principally cash, intangible assets (including goodwill) and other assets maintained for general corporate purposes. A summary of business data for the Company's reportable segments for the years 2002, 2001 and 2000 follows.
Information by Business Segment
Sales
(In thousands) | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
Polymer Products | | | | | | | | | | |
Polymer Additives | | $ | 1,110,804 | | $ | 1,125,910 | | $ | 1,233,656 | |
Polymers | | | 270,954 | | | 292,092 | | | 338,577 | |
Polymer Processing Equipment | | | 172,702 | | | 202,653 | | | 310,490 | |
Eliminations | | | (15,064 | ) | | (13,805 | ) | | (14,175 | ) |
| |
|
| |
|
| |
|
| |
| | | 1,539,396 | | | 1,606,850 | | | 1,868,548 | |
| |
|
| |
|
| |
|
| |
Specialty Products | | | | | | | | | | |
OrganoSilicones | | | 456,601 | | | 432,255 | | | 484,424 | |
Crop Protection | | | 240,142 | | | 245,562 | | | 238,547 | |
Other | | | 310,733 | | | 434,131 | | | 446,911 | |
| |
|
| |
|
| |
|
| |
| | | 1,007,476 | | | 1,111,948 | | | 1,169,882 | |
| |
|
| |
|
| |
|
| |
| | $ | 2,546,872 | | $ | 2,718,798 | | $ | 3,038,430 | |
| |
|
| |
|
| |
|
| |
Operating Profit (Loss)
(In thousands) | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
Polymer Products | | | | | | | | | | |
Polymer Additives | | $ | 79,403 | | $ | 55,723 | | $ | 108,223 | |
Polymers | | | 41,028 | | | 42,243 | | | 68,020 | |
Polymer Processing Equipment | | | (13,766 | ) | | (15,647 | ) | | 24,640 | |
| |
|
| |
|
| |
|
| |
| | | 106,665 | | | 82,319 | | | 200,883 | |
| |
|
| |
|
| |
|
| |
Specialty Products | | | | | | | | | | |
OrganoSilicones | | | 56,031 | | | 46,135 | | | 84,139 | |
Crop Protection | | | 60,241 | | | 79,186 | | | 72,747 | |
Other | | | 7,960 | | | 10,779 | | | 18,468 | |
| |
|
| |
|
| |
|
| |
| | | 124,232 | | | 136,100 | | | 175,354 | |
| |
|
| |
|
| |
|
| |
Corporate | | | (42,144 | ) | | (38,760 | ) | | (45,483 | ) |
Amortization | | | (12,775 | ) | | (38,860 | ) | | (39,271 | ) |
Facility closures, severance and related costs | | | (23,317 | ) | | (114,033 | ) | | (23,148 | ) |
Antitrust investigation costs | | | (6,306 | ) | | — | | | — | |
Impairment of long-lived assets | | | — | | | (80,366 | ) | | — | |
| |
|
| |
|
| |
|
| |
| | $ | 146,355 | | $ | (53,600 | ) | $ | 268,335 | |
| |
|
| |
|
| |
|
| |
Depreciation and Amortization
(In thousands) | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
Polymer Products | | | | | | | | | | |
Polymer Additives | | $ | 59,805 | | $ | 58,765 | | $ | 60,691 | |
Polymers | | | 16,030 | | | 17,347 | | | 15,240 | |
Polymer Processing Equipment | | | 2,584 | | | 2,765 | | | 2,543 | |
| |
|
| |
|
| |
|
| |
| | | 78,419 | | | 78,877 | | | 78,474 | |
| |
|
| |
|
| |
|
| |
Specialty Products | | | | | | | | | | |
OrganoSilicones | | | 31,188 | | | 25,003 | | | 23,293 | |
Crop Protection | | | 8,081 | | | 8,004 | | | 6,994 | |
Other | | | 9,902 | | | 16,644 | | | 15,501 | |
| |
|
| |
|
| |
|
| |
| | | 49,171 | | | 49,651 | | | 45,788 | |
| |
|
| |
|
| |
|
| |
Corporate | | | 18,960 | | | 57,042 | | | 57,755 | |
| |
|
| |
|
| |
|
| |
| | $ | 146,550 | | $ | 185,570 | | $ | 182,017 | |
| |
|
| |
|
| |
|
| |
Segment Assets
(In thousands) | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
Polymer Products | | | | | | | | | | |
Polymer Additives | | $ | 731,241 | | $ | 728,640 | | $ | 909,459 | |
Polymers | | | 120,208 | | | 142,196 | | | 213,795 | |
Polymer Processing Equipment | | | 89,343 | | | 101,498 | | | 122,743 | |
| |
|
| |
|
| |
|
| |
| | | 940,792 | | | 972,334 | | | 1,245,997 | |
| |
|
| |
|
| |
|
| |
Specialty Products | | | | | | | | | | |
OrganoSilicones | | | 382,699 | | | 381,609 | | | 388,244 | |
Crop Protection | | | 146,361 | | | 145,001 | | | 154,741 | |
Other | | | 87,280 | | | 216,080 | | | 311,696 | |
| |
|
| |
|
| |
|
| |
| | | 616,340 | | | 742,690 | | | 854,681 | |
| |
|
| |
|
| |
|
| |
Corporate | | | 1,283,683 | | | 1,517,164 | | | 1,427,649 | |
| |
|
| |
|
| |
|
| |
| | $ | 2,840,815 | | $ | 3,232,188 | | $ | 3,528,327 | |
| |
|
| |
|
| |
|
| |
Capital Expenditures
(In thousands) | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
Polymer Products | | | | | | | | | | |
Polymer Additives | | $ | 42,755 | | $ | 52,614 | | $ | 61,558 | |
Polymers | | | 5,584 | | | 8,987 | | | 13,774 | |
Polymer Processing Equipment | | | 2,608 | | | 4,160 | | | 3,355 | |
| |
|
| |
|
| |
|
| |
| | | 50,947 | | | 65,761 | | | 78,687 | |
| |
|
| |
|
| |
|
| |
Specialty Products | | | | | | | | | | |
OrganoSilicones | | | 16,026 | | | 44,339 | | | 47,760 | |
Crop Protection | | | 5,950 | | | 8,825 | | | 8,054 | |
Other | | | 6,950 | | | 11,742 | | | 11,453 | |
| |
|
| |
|
| |
|
| |
| | | 28,926 | | | 64,906 | | | 67,267 | |
| |
|
| |
|
| |
|
| |
Corporate | | | 20,436 | | | 5,975 | | | 8,860 | |
| |
|
| |
|
| |
|
| |
| | $ | 100,309 | | $ | 136,642 | | $ | 154,814 | |
| |
|
| |
|
| |
|
| |
Equity Method Investments
(In thousands) | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
Polymer Products | | | | | | | | | | |
Polymer Additives | | $ | 40,267 | | $ | 45,924 | | $ | 43,144 | |
Polymers | | | — | | | 1,134 | | | 8,249 | |
Polymer Processing Equipment | | | — | | | — | | | — | |
| |
|
| |
|
| |
|
| |
| | | 40,267 | | | 47,058 | | | 51,393 | |
| |
|
| |
|
| |
|
| |
Specialty Products | | | | | | | | | | |
OrganoSilicones | | | 54 | | | 45 | | | 48 | |
Crop Protection | | | 23,963 | | | 24,465 | | | 20,725 | |
Other | | | — | | | 102 | | | 8,645 | |
| |
|
| |
|
| |
|
| |
| | | 24,017 | | | 24,612 | | | 29,418 | |
| |
|
| |
|
| |
|
| |
Corporate | | | — | | | — | | | 1,750 | |
| |
|
| |
|
| |
|
| |
| | $ | 64,284 | | $ | 71,670 | | $ | 82,561 | |
| |
|
| |
|
| |
|
| |
Geographic Information
Sales are based on location of customer.
Sales
(In thousands) | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
United States | | $ | 1,270,929 | | $ | 1,401,679 | | $ | 1,664,557 | |
Canada | | | 84,234 | | | 91,792 | | | 111,491 | |
Latin America | | | 173,826 | | | 187,903 | | | 179,607 | |
Europe/Africa | | | 689,770 | | | 696,650 | | | 730,519 | |
Asia/Pacific | | | 328,113 | | | 340,774 | | | 352,256 | |
| |
|
| |
|
| |
|
| |
| | $ | 2,546,872 | | $ | 2,718,798 | | $ | 3,038,430 | |
| |
|
| |
|
| |
|
| |
Property, Plant and Equipment
(In thousands) | | 2002 | | 2001 | | 2000 | |
| |
| |
| |
| |
United States | | $ | 569,437 | | $ | 683,140 | | $ | 822,669 | |
Canada | | | 46,636 | | | 43,008 | | | 48,215 | |
Latin America | | | 25,392 | | | 28,429 | | | 15,307 | |
Europe/Africa | | | 283,568 | | | 253,383 | | | 270,435 | |
Asia/Pacific | | | 17,483 | | | 14,023 | | | 25,461 | |
| |
|
| |
|
| |
|
| |
| | $ | 942,516 | | $ | 1,021,983 | | $ | 1,182,087 | |
| |
|
| |
|
| |
|
| |
SUMMARIZED UNAUDITED QUARTERLY FINANCIAL DATA
(In thousands, except per share data) | | 2002 | |
| |
| |
| | First | | Second | | Third | | Fourth | |
| |
| |
| |
| |
| |
Net sales | | $ | 644,838 | | $ | 689,734 | | $ | 624,721 | | $ | 587,579 | |
Gross profit | | | 185,975 | | | 215,175 | | | 206,129 | | | 185,470 | |
Earnings (loss) before cumulative effect of accounting change | | | 6,755 | | | (6,294 | ) | | 12,588 | | | 2,425 | |
Net earnings (loss) | | | (292,226 | ) | | (6,294 | ) | | 12,588 | | | 2,425 | |
Earnings (loss) before cumulative effect of accounting change per common share: | | | | | | | | | | | | | |
Basic | | | .06 | | | (.06 | ) | | .11 | | | .02 | |
Diluted | | | .06 | | | (.06 | ) | | .11 | | | .02 | |
Net earnings (loss) per common share: | | | | | | | | | | | | | |
Basic | | | (2.57 | ) | | (.06 | ) | | .11 | | | .02 | |
Diluted | | | (2.52 | ) | | (.06 | ) | | .11 | | | .02 | |
Dividends per common share | | | .05 | | | .05 | | | .05 | | | .05 | |
Market price per common share: | | | | | | | | | | | | | |
High | | | 12.75 | | | 13.00 | | | 12.90 | | | 10.69 | |
Low | | | 8.46 | | | 10.25 | | | 8.81 | | | 5.44 | |
(In thousands, except per share data) | | 2001 | |
| |
| |
| | First | | Second | | Third | | Fourth | |
| |
| |
| |
| |
| |
Net sales | | $ | 737,936 | | $ | 724,032 | | $ | 651,921 | | $ | 604,909 | |
Gross profit | | | 223,349 | | | 221,030 | | | 197,313 | | | 171,770 | |
Net earnings (loss) | | | 15,770 | | | 13,894 | | | (68,208 | ) | | (85,400 | ) |
Net earnings (loss) per common share: | | | | | | | | | | | | | |
Basic | | | .14 | | | .12 | | | (.60 | ) | | (.76 | ) |
Diluted | | | .14 | | | .12 | | | (.60 | ) | | (.76 | ) |
Dividends per common share | | | .05 | | | .05 | | | .05 | | | .05 | |
Market price per common share: | | | | | | | | | | | | | |
High | | | 12.19 | | | 12.10 | | | 11.08 | | | 9.65 | |
Low | | | 10.06 | | | 9.72 | | | 6.20 | | | 6.35 | |
responsibility for financial statements
Management of the Company is responsible for the accuracy and reliability of the consolidated financial statements and accompanying notes. Such financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and have been audited by KPMG LLP, Independent Certified Public Accountants, whose report is presented herein.
The Company has a system of internal accounting and disclosure controls that includes (1) written financial policies and procedures; (2) an organization structure that segregates duties and defines authority; (3) a code of business ethics that provides guidance to employees with respect to business practices and procedures; (4) an anonymous help line for the communication of illegal or unethical behavior; (5) continuous on site audits and reviews performed by the Company’s internal audit group; (6) quarterly representations from key business functional and financial executives regarding the accuracy of the financial information being reported; and (7) quarterly disclosure committee meetings to evaluate the quality and effectiveness of internal controls for disclosures included in the financial statements filed with the Securities and Exchange Commission. This system of controls is designed to provide reasonable assurance as to the integrity and reliability of the financial statements, the protection of assets from unauthorized use or disposition, and the prevention and detection of fraudulent financial reporting. Such controls are subject to continuous review and are monitored by the Company’s financial management, disclosure committee and internal audit group.
In addition, the Board of Directors pursues its oversight role for the financial statements through its Audit Committee, which consists solely of outside directors. The Audit Committee meets on a regular basis with representatives of management, the internal audit group and KPMG LLP.
| | |
| | |
Vincent A. Calarco President and Chief Executive Officer | | |
| | |
| | |
Peter Barna Senior Vice President and Chief Financial Officer | | |
independent auditors’ report
The Board of Directors and Stockholders
Crompton Corporation
We have audited the accompanying consolidated balance sheets of Crompton Corporation and subsidiaries (the Company) as of December 31, 2002 and 2001, and the related consolidated statements of operations, stockholders’ equity and cash flows for each of the years in the three-year period ended December 31, 2002. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2002 and 2001, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2002, in conformity with accounting principles generally accepted in the United States of America.
As discussed in the Accounting Policies note to the consolidated financial statements, the Company adopted the provisions of Statement of Financial Accounting Standards No. 142, “Goodwill and Other Intangible Assets” on January 1, 2002.
| | |
| | |
Stamford, Connecticut January 31, 2003 | | |
PART III
ITEM 14. CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures
The Company’s management has evaluated, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, the effectiveness of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), as of the end of the period covered by this annual report. Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this annual report.
(b) Changes in Internal Control over Financial Reporting
There was no change in the Company’s internal control over financial reporting that occurred during the fiscal year covered by this annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON
FORM 8-K
| (a) | The following documents are filed as part of this report on Form 10-K/A: |
| 1. | Financial statements and Independent Auditors’ Report, as included in Part II, Item 8 of this Form 10-K/A: |
| (i) | Consolidated Statements of Operations for the years ended December 31, 2002, 2001, and 2000; |
| (ii) | Consolidated Balance Sheets for the years ended December 31, 2002 and 2001; |
| (iii) | Revised Consolidated Statements of Cash Flows for the years ended December 31, 2002, 2001, and 2000; |
| (iv) | Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2002, 2001 and 2000; |
| (v) | Revised Notes to Consolidated Financial Statements; and |
| (vi) | Independent Auditors’ Report of KPMG LLP. |
| 2. | Independent Auditors’ Report and Consent, and Financial Statement Schedule II, “Valuation and Qualifying Accounts,” required by Regulation S-X, were filed with the Company’s 2002 Annual Report on Form 10-K. |
| 3. | The following exhibits are either filed herewith or incorporated herein by reference to the respective reports and registration statements identified in the parenthetical clause following the description of the exhibit: |
Exhibit No. | Description |
| |
2.0 | Agreement and Plan of Reorganization dated as of May 31, 1999, by and among Crompton & Knowles Corporation, Park Merger Co. and Witco Corporation (incorporated by reference to Appendix A to the Joint Proxy Statement-Prospectus dated July 28, 1999, as part of the Registrant’s Registration Statement on Form S-4, Registration No. 333-83901, dated July 28, 1999 (“Joint Proxy Statement-Prospectus S-4 Registration Statement”)). |
2.1 | Amendment No. 1 to Agreement and Plan of Reorganization dated as of July 27, 1999, by and among Crompton & Knowles Corporation, CK Witco Corporation (formerly known as Park Merger Co.) and Witco Corporation (incorporated by reference to Appendix A-1 to the Joint Proxy Statement-Prospectus S-4 Registration Statement). |
2.2 | Agreement and Plan of Merger dated April 30, 1996, by and among Crompton & Knowles, Tiger Merger Corp. and Uniroyal Chemical Corporation (“UCC”) (incorporated by reference to Exhibit 2 to the Crompton & Knowles Form 10-Q for the period ended March 31, 1996). |
2.3 | Purchase Agreement between the Registrant (and its affiliates named therein) and Akzo Nobel Surface Chemistry L.L.C. (and its affiliates named therein), dated as of June 28, 2002 (incorporated by reference to Exhibit 2.1 to the Registrant’s Form 10-Q for the period ended June 30, 2002 (“June 30, 2002 10-Q”)). |
| |
2.4 | Limited Liability Company Agreement by and between Gustafson, Inc. and Trace Chemicals, Inc., effective as of September 23, 1998, (incorporated by reference to Exhibit 2.1 to the Crompton & Knowles Form 8-K/A dated January 21, 1999 (“Form 8-K/A”)). |
2.5 | First Amendment to Limited Liability Company Agreement by and among GT Seed Treatment Inc. (f/k/a Gustafson, Inc.), Ecart Inc. (f/k/a Trace Chemicals, Inc.) and Bayer Corporation, dated as of November 20, 1998, (incorporated by reference to Exhibit 2.2 to Form 8-K/A). |
2.6 | Purchase Agreement by and among the Crompton & Knowles, Uniroyal, Trace Chemicals, Inc. and Gustafson, Inc. as Sellers, and Bayer Corporation, as Purchaser, and Gustafson LLC, as the Company, dated as of November 20, 1998, (incorporated by reference to Exhibit 2.3 to Form 8-K/A). |
2.7 | Purchase Agreement by and between Uniroyal Chemical Co./Cie and Bayer Inc., effective as of November 20, 1998, (incorporated by reference to Exhibit 2.4 to Form 8-K/A). |
2.8 | Partnership Agreement of Gustafson Partnership by and between Uniroyal Chemical Co./Cie and Bayer Inc., effective as of November 20, 1998, (incorporated by reference to Exhibit 2.5 to Form 8-K/A). |
2.9 | Joint Venture Agreement and Shareholders Agreement dated September 18, 1998, by and between Uniroyal and GIRSA S.A. de C.V. (incorporated by reference to Exhibit 2.6 to the Crompton & Knowles Form 10-K for the fiscal year ended December 26, 1998 (“1998 Form 10-K”)). |
2.10 | Stock Purchase Agreement dated as of December 8, 1998, by and among Crompton & Knowles and Ingredient Technology Corporation, as Sellers, and Chr. Hansen Inc., as Purchaser (incorporated by reference to Exhibit 2.7 to the 1998 Form 10- K). |
3(i)(a) | Amended and Restated Certificate of Incorporation of the Registrant dated September 1, 1999 (incorporated by reference to Exhibit 3(i)(a) to the Registrant’s Form 10-K for the fiscal year ended December 31, 2001 (“2001 Form 10-K”)). |
3(i)(b) | Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant dated April 27, 2000 (incorporated by reference to Exhibit 3(i)(b) to the Registrant’s 2001 Form 10-K). |
3(i)(c) | Certificate of Change of Location of Registered Office and of Registered Agent dated May 18, 2000 (incorporated by reference to Exhibit 3(i)(c) to the Registrant’s 2001 Form 10-K). |
3(ii) | By-laws of the Registrant (incorporated by reference to Exhibit 3(ii) to the Registrant’s 2001 Form 10-K). |
4.1 | Rights Agreement dated as of September 2, 1999, by and between the Registrant and ChaseMellon Shareholder Services, L.L.C., as Rights Agent (incorporated by reference to Form 8-A dated September 28, 1999). |
4.2 | Form of $600 Million 364-Day Credit Agreement dated as of October 28, 1999, by and among the Registrant, certain subsidiaries of the Registrant, various banks, The Chase Manhattan Bank, as Syndication Agent, Citibank, N.A., as Administrative Agent and Bank of America, N.A. and Deutsche Bank Securities Inc., as Co-Documentation Agents (incorporated by reference to Exhibit 4.1 to the 10-Q for the quarter ended September 30, 1999 (“September 30, 1999 10-Q”)). |
4.3 | Form of $125 Million Amended and Restated 364-Day Credit Agreement dated as of September 24, 2001, among the Registrant, certain subsidiaries of the Registrant, various banks, The Chase Manhattan Bank, as Syndication Agent, Citibank, N.A., as Administrative Agent, Bank of American, N.A., as Documentation Agent and J.P. Morgan Securities Inc., as Lead Arranger and Sole Bookrunner (incorporated by reference to Exhibit 4.1 to the 10-Q for the quarter ended September 30, 2001 (“September 30, 2000 10-Q”)). |
4.4 | First Amendment dated as of December 21, 2001, to the Amended and Restated 364-Day Credit Agreement dated as of October 28, 1999, (as amended and restated in the form of the Amended and Restated Credit Agreement as of September 24, 2001) among the Registrant, certain subsidiaries of the Registrant, various banks, J.P. Morgan Bank (formerly known as The Chase Manhattan Bank), as Syndication Agent, Citicorp USA, Inc. (as successor to Citibank, N.A.), as Administrative Agent, and Bank of America, N.A. and Deutsche Bank Alex Brown Inc., as Co-Documentation Agents (incorporated by reference to Exhibit 4.7 to the Registrant’s 2001 Form 10-K). |
4.5 | Waiver No. 1 dated as of June 30, 2001, to the 364-Day Credit Agreement dated as of October 28, 1999 as amended as of October 26, 2000, among the Registrant, certain subsidiaries of the Registrant, various banks, The Chase Manhattan Bank, as Syndication Agent, Citibank, N.A., as Administrative Agent and Bank of America, N.A. and Deutsche Bank Securities Inc., as Co-Documentation Agents (incorporated by reference to Exhibit No. 4.1 to the 10-Q for the quarter ended June 30, 2001 (“June 30, 2001 10-Q”)). |
4.6 | Form of $400 Million Five-Year Credit Agreement dated as of October 28, 1999, by and among the Registrant, certain subsidiaries of the Registrant, various banks, The Chase Manhattan Bank, as Syndication Agent, Citibank, N.A., as Administrative Agent and Bank of America, N.A. and Deutsche Bank Securities Inc., as Co-Documentation Agents (incorporated by reference to Exhibit 4.2 to the September 30, 1999 10-Q). |
4.7 | First Amendment dated as of September 24, 2001, to the Five- Year Credit Agreement dated as of October 28, 1999, by and among the Registrant, certain subsidiaries of the Registrant, various banks, The Chase Manhattan Bank, as Syndication Agent, Citibank, N.A., as Administrative Agent, Bank of America, N.A.and Deutsche Bank Alex Brown Inc., as Co-Documentation Agents, and J.P. Morgan Securities Inc., as Lead Arranger and Sole Bookrunner (incorporated by reference to the September 30, 2001 10-Q). |
4.8 | Second Amendment dated as of December 21, 2001, to the Five- Year Credit Agreement dated as of October 28, 1999, by and among the Registrant, certain subsidiaries of the Registrant, various banks, J.P. Morgan Chase Bank (formerly known as The Chase Manhattan Bank), as Syndication Agent, Citicorp USA, Inc. (as successor to Citibank, N.A.), as Administrative Agent and Bank of America, N.A. and Deutsche Bank Alex Brown Inc., as Co-Documentation Agents (incorporated by reference to Exhibit 4.11 to the Registrant’s 2001 Form 10-K). |
4.9 | Third Amendment dated as of May 8, 2002, to the Five-Year Credit Agreement dated as of October 28, 1999, by and among the Registrant, certain subsidiaries of the Registrant, various banks, J. P. Morgan Chase (formerly known as The Chase Manhattan Bank), as Syndication Agent, Citicorp USA, Inc. (as successor to Citibank, N.A.), as Administrative Agent and Bank of America, N.A. and Deutsche Bank Securities Inc. (formerly known as Deutsche Bank Alex Brown Inc.), as Co-Documentation Agents (incorporated by reference to the Registrant’s June 30, 2002 10-Q). |
| |
4.10 | Waiver No. 1 dated as of June 30, 2001, to the Five-Year Credit Agreement dated as of October 28, 1999, by and among the Registrant, certain subsidiaries of the Registrant, various banks, The Chase Manhattan Bank, as Syndication Agent, Citibank, N.A., as Administrative Agent and Bank of America, N.A. and Deutsche Bank Securities Inc., as Co-Documentation Agents (incorporated by reference to Exhibit 4.2 to the June 30, 2001 Form 10-Q). |
4.11 | Form of Indenture, dated as of March 1, 2000, by and between the Registrant and Citibank, N.A., relating to $600 Million of 8 1/2% Senior Notes due 2005, including as Annex A thereto, Form of Senior Note Pledge Agreement by and among the Registrant, certain foreign subsidiaries of the Registrant, and Citibank, N.A., as Collateral Agent (incorporated by reference to Exhibit 4.13 of the 1999 Form 10-K). |
4.12 | Form of Purchase Agreement, dated as of March 2, 2000, by and among the Registrant, as Seller, and Merrill Lynch, ABN AMRO Incorporated, Banc of America Securities LLC, Chase Securities Inc., Deutsche Bank Securities Inc., Goldman, Sachs & Co. and Salomon Smith Barney Inc. (together, the “Initial Purchasers”), relating to $600 Million of 8 1/2% Senior Notes due 2005 (incorporated by reference to Exhibit 4.14 of the 1999 Form 10-K). |
4.13 | Form of Indenture, dated as of February 1, 1993, by and between Witco and the Chase Manhattan Bank, N.A., as Trustee, relating to Witco’s 6.60% Notes due 2003, 7.75% Debentures due 2023, 6 1/8% Notes due 2006 and 6 7/8% Debentures due 2026, including form of securities (incorporated by reference to Post-Effective Amendment No. 2 to the Registration Statement on Form S-3, Registration No. 33-58066, filed March 19, 1993). |
4.14 | Form of First Supplemental Indenture, dated February 1, 1996, by and among Witco, Chase Manhattan Bank, N.A., the Initial Trustee, and Fleet National Bank of Connecticut, the Note Trustee, relating to Witco’s 6 1/8% Notes due 2006 and 6 7/8% Notes due 2026 (incorporated by reference to Registration Statement on Form S-3, Registration Number 33- 65203, filed January 25, 1996). |
4.15 | Form of $600 Million of 8.50% Senior Notes due 2005, dated June 9, 2000, registered for public trading with the U.S.Securities and Exchange Commission and issued in exchange for identical securities sold in March 2000, which were not registered for public trading (incorporated by reference to Exhibit 4 of the Registrant’s Form 10-Q for the quarter ended June 30, 2000). |
10.1+ | Supplemental Medical Reimbursement Plan (incorporated by reference to Exhibit 10(n) to the Crompton & Knowles Form 10-K for the fiscal year ended December 27, 1980). |
10.2+ | Supplemental Dental Reimbursement Plan (incorporated by reference to Exhibit 10(o) to the Crompton & Knowles Form 10-K for the fiscal year ended December 27, 1980). |
10.3+ | Form of Employment Agreement dated as of July 29, 2002, by and between the Registrant and various of its executive officers (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 10-Q for the period ended September 30, 2002 (“September 30, 2002 Form 10-Q”)). |
10.4+ | Form of Employment Agreement dated as of August 21, 1996, between a subsidiary of the Registrant and three executive officers of the Registrant (incorporated by reference to Exhibit 10.28 to the UCC/Uniroyal Form 10-K for the fiscal year ended September 28, 1996). |
10.5+ | Form of Supplemental Retirement Agreement dated as of August 21, 1996, between a subsidiary of the Registrant and two executive officers of the Registrant (incorporated by reference to Exhibit 10.29 to the UCC/Uniroyal Form 10-K for the fiscal year ended September 28, 1996). |
10.6+ | Form of Supplemental Retirement Agreement dated as of August 21, 1996, between a subsidiary of the Registrant and two executive officers of the Registrant (incorporated by reference to Exhibit 10.30 to the UCC/Uniroyal Form 10-K for the fiscal year ended September 28, 1996). |
10.7+ | Supplemental Retirement Agreement Trust Agreement dated October 20, 1993, between Crompton & Knowles and Shawmut Bank, N.A. (incorporated by reference to Exhibit 10(l) to the Crompton & Knowles Form 10-K for the fiscal year ended December 25, 1993). |
10.8(i)+ | Crompton Corporation Benefit Equalization Plan, amended as of April 30, 2002 (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 10-Q for the period ended March 31, 2002 (“March 31, 2002 Form 10-Q”). |
10.8(ii)+ | Crompton Corporation Amended Benefit Equalization Plan, dated October 22, 2002 (incorporated by reference to Exhibit 10.2 to the Registrant’s September 30, 2002 Form 10-Q). |
10.9+ | Amended Benefit Equalization Plan Trust Agreement dated October 20, 1993, between Crompton & Knowles and Shawmut Bank, N.A. (incorporated by reference to Exhibit 10(n) to the Crompton & Knowles Form 10-K for the fiscal year ended December 25, 1993). |
10.10+ | Amended Crompton Corporation 1988 Long Term Incentive Plan (incorporated by reference to Exhibit 10.10+ to the Registrant’s 2001 Form 10-K). |
10.11 | Trust Agreement dated as of May 15, 1989, between Crompton & Knowles and Shawmut Worcester County Bank, N.A. and First Amendment thereto dated as of February 8, 1990 (incorporated by reference to Exhibit 10(w) to the Crompton & Knowles Form 10-K for the fiscal year ended December 30, 1989). |
10.12+ | Restricted Stock Plan for Directors of Crompton & Knowles approved by the stockholders on April 9, 1991 (incorporated by reference to Exhibit 10(z) to the Crompton & Knowles Form 10-K for the fiscal year ended December 28, 1991). |
10.13+ | Amended 1993 Stock Option Plan for Non-Employee Directors (incorporated by reference to Exhibit 10.21 to the Crompton & Knowles Form 10-K for the fiscal year ended December 26, 1998). |
10.14+ | UCC Purchase Right Plan, as amended and restated as of March 16, 1995 (incorporated by reference to Exhibit 10.1 to the UCC Form 10-Q for the period ended April 2, 1995 (“UCC April 1995 Form 10-Q”)). |
10.15+ | UCC 1993 Stock Option Plan (incorporated by reference to Exhibit 28.1 to UCC’s Registration Statement No. 33-62030 on Form S-8, filed on May 4, 1993). |
10.16+ | Form of Amendment No. 2 to the UCC 1993 Stock Option Plan (incorporated by reference to Exhibit 10.2 to the UCC April 1995 Form 10-Q). |
10.17+ | Form of Executive Stock Option Agreement, dated as of November 15, 1993 (incorporated by reference to Exhibit 10.22 to the UCC 1994 Form 10-K). |
10.18+ | Form of Amended and Restated 1996 - 1998 Long Term Performance Award Agreement entered into in 1996 between Crompton & Knowles or one of its subsidiaries and thirteen of the executive officers of Crompton & Knowles (incorporated by reference to Exhibit 10.27 to the Crompton & Knowles Form 10-K for the fiscal year ended December 27, 1997). |
10.19 | Second Amended and Restated Lease Agreement between the Middlebury Partnership, as Lessor, and Uniroyal, as Lessee, dated as of August 28, 1997 (incorporated by reference to Exhibit 10 to the UCC/Uniroyal 10-Q for the quarter ended September 27, 1997). |
10.20 | Form of Receivables Sale Agreement, dated as of December 11, 1998, by and among Crompton & Knowles, as Initial Collection Agent, Crompton & Knowles Receivables Corporation, as Seller, ABN AMRO Bank N.V., as Agent, the Enhancer, and the Liquidity Provider, and Windmill Funding Corporation (incorporated by reference to Exhibit 10.291 to the Crompton & Knowles Form 10-K for the fiscal year ended December 26, 1998). |
10.201 | Amended and Restated Receivables Sale Agreement, dated as of January 18, 2002, among Crompton & Knowles Receivables Corporation, as the Seller, the Registrant, as the Initial Collection Agent, ABN AMRO Bank N.V., as the Agent, certain liquidity providers, ABN AMRO Bank, N.V., as the Enhancer, and Amsterdam Funding Corporation (incorporated by reference to Exhibit 10.201 to the Registrant’s 2001 Form 10-K). |
10.202 | First Amendment dated as of January 17, 2003, to the Amended and Restated Receivables Sale Agreement, dated as of January 18, 2002, among Crompton & Knowles Receivables Corporation, as the Seller, the Registrant, as the Initial Collection Agent, ABN AMRO Bank N.V., as the Agent, certain liquidity providers, ABN AMRO Bank, N.V., as the Enhancer, and Amsterdam Funding Corporation.** |
10.203 | Form of Receivables Purchase Agreement, dated as of December 11, 1998, by and among Crompton & Knowles, as Initial Collection Agent, and certain of its subsidiaries, as Sellers, |
| Crompton & Knowles Receivables Corporation, as Buyer, and ABN AMRO Bank N.V., as Agent (incorporated by reference to Exhibit 10.292 to the Crompton & Knowles Form 10-K for the fiscal year ended December 26, 1998). |
10.204 | Amendment Number 1 dated as of December 9, 1999, to the Receivables Purchase Agreement, dated as of December 11, 1998, by and among CK Witco Corporation (as successor by merger to Crompton & Knowles), as Initial Collection Agent, and certain of its subsidiaries, as Sellers, Crompton & Knowles Receivables Corporation, as Buyer, and ABN AMRO Bank N.V., as Agent (incorporated by reference to Exhibit 10.265 to Form 10- K for the fiscal year ended December 31, 2000 (“2000 Form 10- K”). |
10.205 | Amendment Number 2 dated as of November 20, 2000, to the Receivables Purchase Agreement, dated as of December 11, 1998, by and among the Registrant (as successor to Crompton & Knowles), as Initial Collection Agent, and certain of its subsidiaries, as Sellers, Crompton & Knowles Receivables Corporation, as Buyer, and ABN AMRO Bank N.V., as Agent (incorporated by reference to Exhibit 10.266 to the 2000 Form 10-K). |
10.206 | Amendment Number 3 dated as of February 1, 2001, to the Receivables Purchase Agreement dated as of December 11, 1998, by and among the Registrant (as successor to Crompton & Knowles), as Initial Collection Agent, and certain of its subsidiaries, as Sellers, Crompton & Knowles Receivables Corporation, as Buyer, and ABN AMRO Bank N.V., as Agent (incorporated by reference to Exhibit 10.267 to the 2000 Form 10-K). |
10.207 | Letter Agreement dated as of January 18, 2002, to the Receivables Purchase Agreement dated as of December 11, 1998, by and among the Registrant (as successor to Crompton & Knowles), as Initial Collection Agent, and certain of its subsidiaries, as Sellers, Crompton & Knowles Receivables Corporation, as Buyer, and Crompton Sales Company, Inc. and ABN AMRO Bank N.V., as Agent (incorporated by reference to Exhibit 10.206 to the Registrant’s 2001 Form 10-K). |
10.21+ | Amended Crompton Corporation 1998 Long Term Incentive Plan (incorporated by reference to Exhibit 10.21 to the Registrant’s 2001 Form 10-K). |
10.22+ | Amended and Restated Employment Agreement by and between Crompton & Knowles and Vincent A. Calarco dated May 31, 1999 (incorporated by reference to Exhibit 10.1 to the Crompton & Knowles Form 10-Q for the quarter ended June 26, 1999). |
10.23+ | Form of Merger Synergy Restricted Stock Agreement, dated as of October 19, 1999, by and between the Registrant and various of its executive officers (incorporated by reference to Exhibit 10.32 to the 1999 Form 10-K). |
10.24+ | Form of Supplemental Retirement Agreement, dated as of October 21, 1999, by and between the Registrant and various of its executive officers (incorporated by reference to Exhibit 10.35 of the 1999 Form 10-K). |
10.25+ | Form of 2001-2002 Long Term Incentive Award Agreement, dated as of January 31, 2001, by and between the Registrant and various of its executive officers (incorporated by reference to Exhibit 10 to the 10-Q for the quarter ended March 31, 2001). |
10.26+ | Form of 2001 Management Incentive Plan dated as of March 20, 2001, by and between the Registrant and various key management personnel (incorporated by reference to Exhibit 10.26+ to the Registrant’s 2001 Form 10-K). |
10.27+ | Form of 2002 Management Incentive Plan dated as of February 8, 2002, by and between the Registrant and various key management personnel (incorporated by reference to Exhibit 10.27+ to the Registrant’s 2001 Form 10-K). |
10.28+ | Form of 2002-2004 Long-Term Incentive Award Agreement, dated as of March 26, 2002, by and between the Registrant and various of its executive officers (incorporated by reference to Exhibit 10.1 to the Registrant’s March 31, 2002 Form 10-Q). |
13 | 2002 Annual Report to Stockholders of the Registrant.** (Not to be deemed filed with the Securities and Exchange Commission except those portions expressly incorporated by reference to Exhibit 13 to the Registrant’s Form 10-K for the year-ended December 31, 2002. |
21 | Subsidiaries of the Registrant.** |
23 | Consent of independent auditors. (filed herewith*). |
24 | Power of attorney from directors and executive officers of the Registrant authorizing signature of this report. (Original on file at principal executive offices of Registrant.) **. |
31.1 | Certification of Periodic Financial Reports by the Registrant’s Chief Executive Officer (Section 302) (filed herewith*) |
31.2 | Certification of Periodic Financial Reports by the Registrant’s Chief Financial Officer (Section 302) (filed herewith*) |
32.1 | Certification of Periodic Financial Reports by the Registrant’s Chief Executive Officer (Section 906) (filed herewith*) |
32.2 | Certification of Periodic Financial Reports by the Registrant’s Chief Financial Officer (Section 906) (filed herewith*) |
* Copies of these Exhibits are annexed to this report on Form 10-K/A provided to the Securities and Exchange Commission and the New York Stock Exchange.
** Copies of these Exhibits are annexed to the Company’s Annual Report on Form 10-K for the year ended December 31, 2002 provided to the Securities and Exchange Commission and the New York Stock Exchange.
+ This Exhibit is a compensatory plan, contract or arrangement in which one or more directors or executive officers of the Registrant participate.
(b) Reports on Form 8-K filed in fourth quarter 2002
During the fiscal fourth quarter of 2002, the Registrant filed a Current Report on Form 8-K dated December 12, 2002, reporting on items 5 and 7, and a Current Report on Form 8-K dated October 8, 2002, reporting on items 5 and 7.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | CROMPTON CORPORATION (Registrant) |
Date: December 23, 2003
| | | By:
| /s/Peter Barna |
| | | |
|
| | | Peter Barna Senior Vice President & Chief Financial Officer |
| | | | | |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the date indicated.
Name | Title |
Vincent A. Calarco* | Chairman of the Board, President, and Director (Principal Executive Officer) |
Peter Barna* | Senior Vice President (Chief Financial Officer) |
Michael F. Vagnini* | Vice President and Controller (Principal Accounting Officer) |
Robert A. Fox* | Director |
Roger L. Headrick* | Director |
Leo I. Higdon, Jr.* | Director |
C. A. Piccolo* | Director |
Bruce F. Wesson* | Director |
Patricia K. Woolf* | Director |
Date: December 23, 2003
| | | *By:
| /s/Peter Barna |
| | | |
|
| | | Peter Barna as attorney-in-fact |